Sheppard, Mullin, Richter & Hampton LLP‘s ’flexible and business oriented’ practice assists clients with the management of their patent portfolios, advising on patent prosecution strategies and representing them in court where infringements occur, while also supporting clients in negotiations with the FDA over labelling issues and approvals for novel drugs. Based in New York, the practice leadership consists of Jeffrey Fessler, who focuses on life sciences transactions, and Scott Liebman, who accompanies pharmaceutical, biotech and medical devices clients through FDA procedures. Former team co-head Allison Fulton took up an in house post in February 2023.
Testimonials
Collated independently by Legal 500 research team.
‘Sheppard Mullin has been a reliable partner for our company. We can always rely on SM to provide excellent legal service, no matter what the legal issues are. SM's client service is something that we greatly treasure and appreciate. SM's key strength is its broad legal expertise and excellent attorneys.’
‘Sheppard Mullin teams have always been flexible and business oriented. We receive practical advice that does not require reading a long memo, but can apply it to our business the same day. Highly recommend.’
‘They are very knowledgeable about companies like ours.’
‘Jeffrey Fessler is great.’
'Very knowledgeable and responsive. Provide well thought out advice/counsel.'
'The team is easy to work with and knowledgeable in pharma. They do not just provide legal advice, but work to find solutions.'
'Scott Liebman and Alexandra Kitson are practical in their advice and really understand the pharma industry. This team understands the business and provides solutions that can be operationalized.'
'Fantastic patent prosecution practice in the life sciences space.'
Key clients
- Pacira Biosciences Inc.
- Gilead Sciences, Inc./Kite Pharma
- Global Blood Therapeutics, Inc.
- Edwards Lifesciences Corporation
- Unicycive Therapeutics
- AIS Healthcare
- Ladenburg Thalmann
- Hillstream BioPharma
- Aditxt, Inc.
- Hepion Pharmaceuticals, Inc.
Work highlights
- Represented Pacira against three compounding pharmacies in federal Lanham Act cases concerning false and misleading advertisement and marketing materials.
- Advised Gilead Sciences, Inc. on the management of its patent portfolio.
- Represented Global Blood Therapeutics in connection with its patent portfolio in relation to Oxbryta, a drug aimed at treating haemolytic anaemia in sickle cell patients.
Practice head
The lawyer(s) leading their teams.
Jeffrey Fessler, Scott Liebman